AstraZeneca Looks To Deliver On Its Promises In Oncology
Global Head of Oncology Dave Fredrickson took over the commercial leadership role in October. Now he is overseeing several key growth drivers, including Imfinizi and Lynparza, while building out a new hematology franchise. Fredrickson talked with Scrip about AstraZeneca's oncology strategy at ASCO.
You may also be interested in...
The company stopped the Phase III ADAURA study for Tagrisso early due to overwhelming efficacy and the US FDA approved selumetinib in a rare pediatric disease.
AZ is counting on Calquence’s safety profile to gain ground against AbbVie/J&J’s blockbuster BTK inhibitor Imbruvica.
Full PACIFIC data show strong overall survival benefit in all comers, though not in a post hoc analysis of those with low PD-L1 expression, about 20% of the population.